A Phase I, first-in-human study of ISB 2001 in R/R myeloma: dose escalation results

0 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Hang Quach, MBBS(Hons), SpecCertOC, FRACP, FRCPA, MD, St. Vincent’s Hospital & University of Melbourne, Melbourne, Australia, presents the findings of the dose escalation portion of a Phase I, first-in-human study (NCT05862012) investigating ISB 2001 in patients with relapsed/refractory (R/R) multiple myeloma (MM). Prof. Quach highlights that this BCMAxCD38xCD3-targeting trispecific antibody has demonstrated a favorable safety profile and remarkable efficacy in a heavily pretreated patient population, offering renewed hope for patients with limited treatment options. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Category
Oncology
Be the first to comment

Up Next